BioNTech Looks For Faster Entry Into Cancer Therapies As COVID-19 Recedes
Aims To Reach Market By 2026
Executive Summary
BioNTech continues to earn big money from its COVID-19 vaccine, but wants to become an on-market cancer company sooner rather than later.